1050 related articles for article (PubMed ID: 33545090)
1. Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study.
Marks M; Millat-Martinez P; Ouchi D; Roberts CH; Alemany A; Corbacho-Monné M; Ubals M; Tobias A; Tebé C; Ballana E; Bassat Q; Baro B; Vall-Mayans M; G-Beiras C; Prat N; Ara J; Clotet B; Mitjà O
Lancet Infect Dis; 2021 May; 21(5):629-636. PubMed ID: 33545090
[TBL] [Abstract][Full Text] [Related]
2. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study.
Singanayagam A; Hakki S; Dunning J; Madon KJ; Crone MA; Koycheva A; Derqui-Fernandez N; Barnett JL; Whitfield MG; Varro R; Charlett A; Kundu R; Fenn J; Cutajar J; Quinn V; Conibear E; Barclay W; Freemont PS; Taylor GP; Ahmad S; Zambon M; Ferguson NM; Lalvani A;
Lancet Infect Dis; 2022 Feb; 22(2):183-195. PubMed ID: 34756186
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study.
Ng OT; Marimuthu K; Koh V; Pang J; Linn KZ; Sun J; De Wang L; Chia WN; Tiu C; Chan M; Ling LM; Vasoo S; Abdad MY; Chia PY; Lee TH; Lin RJ; Sadarangani SP; Chen MI; Said Z; Kurupatham L; Pung R; Wang LF; Cook AR; Leo YS; Lee VJ
Lancet Infect Dis; 2021 Mar; 21(3):333-343. PubMed ID: 33152271
[TBL] [Abstract][Full Text] [Related]
4. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 incidence, transmission and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020-2021.
Cohen C; Kleynhans J; von Gottberg A; McMorrow ML; Wolter N; Bhiman JN; Moyes J; du Plessis M; Carrim M; Buys A; Martinson NA; Kahn K; Tollman S; Lebina L; Wafawanaka F; du Toit J; Xavier Gómez-Olivé F; Dawood FS; Mkhencele T; Sun K; Viboud C; ; Tempia S
medRxiv; 2021 Dec; ():. PubMed ID: 34909794
[TBL] [Abstract][Full Text] [Related]
6. PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial.
Nanni O; Viale P; Vertogen B; Lilli C; Zingaretti C; Donati C; Masini C; Monti M; Serra P; Vespignani R; Grossi V; Biggeri A; Scarpi E; Galardi F; Bertoni L; Colamartini A; Falcini F; Altini M; Massa I; Gaggeri R; Martinelli G
Trials; 2020 Jul; 21(1):689. PubMed ID: 32736597
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Clinical and Virological Characteristics of SARS-CoV-2 Infection Among Children Aged 0 to 4 Years and Their Household Members.
Karron RA; Hetrich MK; Na YB; Knoll MD; Schappell E; Meece J; Hanson E; Tong S; Lee JS; Veguilla V; Dawood FS;
JAMA Netw Open; 2022 Aug; 5(8):e2227348. PubMed ID: 36044218
[TBL] [Abstract][Full Text] [Related]
9. Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
O'Brien MP; Forleo-Neto E; Sarkar N; Isa F; Hou P; Chan KC; Musser BJ; Bar KJ; Barnabas RV; Barouch DH; Cohen MS; Hurt CB; Burwen DR; Marovich MA; Brown ER; Heirman I; Davis JD; Turner KC; Ramesh D; Mahmood A; Hooper AT; Hamilton JD; Kim Y; Purcell LA; Baum A; Kyratsous CA; Krainson J; Perez-Perez R; Mohseni R; Kowal B; DiCioccio AT; Geba GP; Stahl N; Lipsich L; Braunstein N; Herman G; Yancopoulos GD; Weinreich DM;
JAMA; 2022 Feb; 327(5):432-441. PubMed ID: 35029629
[TBL] [Abstract][Full Text] [Related]
10. A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19.
Mitjà O; Corbacho-Monné M; Ubals M; Alemany A; Suñer C; Tebé C; Tobias A; Peñafiel J; Ballana E; Pérez CA; Admella P; Riera-Martí N; Laporte P; Mitjà J; Clua M; Bertran L; Sarquella M; Gavilán S; Ara J; Argimon JM; Cuatrecasas G; Cañadas P; Elizalde-Torrent A; Fabregat R; Farré M; Forcada A; Flores-Mateo G; López C; Muntada E; Nadal N; Narejos S; Nieto A; Prat N; Puig J; Quiñones C; Ramírez-Viaplana F; Reyes-Urueña J; Riveira-Muñoz E; Ruiz L; Sanz S; Sentís A; Sierra A; Velasco C; Vivanco-Hidalgo RM; Zamora J; Casabona J; Vall-Mayans M; González-Beiras C; Clotet B;
N Engl J Med; 2021 Feb; 384(5):417-427. PubMed ID: 33289973
[TBL] [Abstract][Full Text] [Related]
11. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 viral load is associated with risk of transmission to household and community contacts.
Bhavnani D; James ER; Johnson KE; Beaudenon-Huibregtse S; Chang P; Rathouz PJ; Weldon M; Matouschek A; Young AE
BMC Infect Dis; 2022 Aug; 22(1):672. PubMed ID: 35931971
[TBL] [Abstract][Full Text] [Related]
13. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial.
Alemany A; Millat-Martinez P; Corbacho-Monné M; Malchair P; Ouchi D; Ruiz-Comellas A; Ramírez-Morros A; Rodríguez Codina J; Amado Simon R; Videla S; Costes G; Capdevila-Jáuregui M; Torrano-Soler P; San José A; Bonet Papell G; Puig J; Otero A; Ruibal Suarez JC; Zarauza Pellejero A; Llopis Roca F; Rodriguez Cortez O; Garcia Garcia V; Vidal-Alaball J; Millan A; Contreras E; Grifols JR; Ancochea À; Galvan-Femenia I; Piccolo Ferreira F; Bonet M; Cantoni J; Prat N; Ara J; Forcada Arcarons A; Farré M; Pradenas E; Blanco J; Àngel Rodriguez-Arias M; Fernández Rivas G; Marks M; Bassat Q; Blanco I; Baro B; Clotet B; Mitjà O;
Lancet Respir Med; 2022 Mar; 10(3):278-288. PubMed ID: 35150610
[TBL] [Abstract][Full Text] [Related]
14. Upper respiratory tract SARS-CoV-2 RNA loads in symptomatic and asymptomatic children and adults.
Costa R; Bueno F; Albert E; Torres I; Carbonell-Sahuquillo S; Barrés-Fernández A; Sánchez D; Padrón C; Colomina J; Lázaro Carreño MI; Bretón-Martínez JR; Martínez-Costa C; Navarro D
Clin Microbiol Infect; 2021 Dec; 27(12):1858.e1-1858.e7. PubMed ID: 34384874
[TBL] [Abstract][Full Text] [Related]
15. Contact Settings and Risk for Transmission in 3410 Close Contacts of Patients With COVID-19 in Guangzhou, China : A Prospective Cohort Study.
Luo L; Liu D; Liao X; Wu X; Jing Q; Zheng J; Liu F; Yang S; Bi H; Li Z; Liu J; Song W; Zhu W; Wang Z; Zhang X; Huang Q; Chen P; Liu H; Cheng X; Cai M; Yang P; Yang X; Han Z; Tang J; Ma Y; Mao C
Ann Intern Med; 2020 Dec; 173(11):879-887. PubMed ID: 32790510
[TBL] [Abstract][Full Text] [Related]
16. Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study.
Jing QL; Liu MJ; Zhang ZB; Fang LQ; Yuan J; Zhang AR; Dean NE; Luo L; Ma MM; Longini I; Kenah E; Lu Y; Ma Y; Jalali N; Yang ZC; Yang Y
Lancet Infect Dis; 2020 Oct; 20(10):1141-1150. PubMed ID: 32562601
[TBL] [Abstract][Full Text] [Related]
17. Epidemiological and viral features of a cohort of SARS-CoV-2 symptomatic and asymptomatic individuals in an area of the Colombian Caribbean.
Mattar S; Martinez-Bravo C; Rivero R; Contreras H; Faccini-Martínez ÁA; Guzman-Teran C; Galeano K; Alvis-Guzman N; Contreras V; Arrieta G; Gonzalez-Tous M; Miranda J; Ospina M; Camargo-Assis F; Mercado-Reyes M; Garay E; Garcia-Perez A; Lopez Y; Tique V
Ann Clin Microbiol Antimicrob; 2020 Dec; 19(1):58. PubMed ID: 33287846
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020-21.
Cohen C; Kleynhans J; von Gottberg A; McMorrow ML; Wolter N; Bhiman JN; Moyes J; du Plessis M; Carrim M; Buys A; Martinson NA; Kahn K; Tollman S; Lebina L; Wafawanaka F; du Toit JD; Gómez-Olivé FX; Dawood FS; Mkhencele T; Sun K; Viboud C; Tempia S;
Lancet Infect Dis; 2022 Jun; 22(6):821-834. PubMed ID: 35298900
[TBL] [Abstract][Full Text] [Related]
19. A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial.
García IG; Rodriguez-Rubio M; Mariblanca AR; de Soto LM; García LD; Villatoro JM; Parada JQ; Meseguer ES; Rosales MJ; González J; Arribas JR; Carcas AJ; de la Oliva P; Borobia AM
Trials; 2020 Jun; 21(1):466. PubMed ID: 32493475
[TBL] [Abstract][Full Text] [Related]
20. Use of an antiviral mouthwash as a barrier measure in the SARS-CoV-2 transmission in adults with asymptomatic to mild COVID-19: a multicentre, randomized, double-blind controlled trial.
Carrouel F; Valette M; Gadea E; Esparcieux A; Illes G; Langlois ME; Perrier H; Dussart C; Tramini P; Ribaud M; Bouscambert-Duchamp M; Bourgeois D
Clin Microbiol Infect; 2021 Oct; 27(10):1494-1501. PubMed ID: 34044151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
